Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
Kapitza
Christoph
C
Profil Institut für Stoffwechselforschung GmbH, Hellersbergstrasse 9, D-41460 Neuss, Germany. christoph.kapitza@profil.com
Zdravkovic
Milan
M
Zijlstra
Eric
E
Segel
Stine
S
Heise
Tim
T
Flint
Anne
A
D000328:Adult; D019540:Area Under Curve; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D007279:Injections, Subcutaneous / Q000009:adverse effects / Q000706:statistics & numerical data*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged
D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1